Get the Daily Brief
Latest Biotech News
Major Progress in Oncology Diagnostics and Therapies
Innovations in oncology continue to accelerate with new diagnostic platforms and targeted therapies. Dana-Farber introduced MARLIN, an AI-driven methylation-based leukemia subtype classifier,...
Advances in Sustainable Agriculture and Environmental Biotechnology
Researchers are pioneering sustainable approaches to agriculture and environmental remediation. Studies reveal innovative methods such as using artificial plant devices powered by sunlight to...
Immunotherapy and Immune Modulation Expand Cancer Treatment Options
Emerging research in immuno-oncology uncovers novel mechanisms and therapeutic strategies. A study in Cell Research demonstrated that blocking NNMT in tumor-associated fibroblasts reactivates...
Innovations in Diagnostics and Imaging Technologies
Cutting-edge technological advances are transforming diagnostics and medical imaging. Heartflow secured FDA clearance for its next-generation plaque analysis algorithm, improving detection by 21%....
Biotech Industry Movements: Investments, Funding, and Leadership Changes
Financial and organizational shifts shape the biotech landscape as firms secure funds and realign leadership. Sanofi and its venture arm Sanofi Ventures boosted biotech investments with an...
Pfizer's $7.3B Metsera Takeover Fuels Obesity Drug Ambitions
Pfizer has announced its acquisition of Metsera for up to $7.3 billion, marking its reentry into the obesity therapeutics market. The deal includes upfront cash and contingent value rights tied to...
FDA Clears Subcutaneous Keytruda Injection Within One Minute
The U.S. FDA has approved Merck’s Keytruda Qlex, the first subcutaneous immune checkpoint inhibitor administered in about one minute. This new administration method offers a significant reduction...
Ionis Achieves Phase 3 Success for Alexander Disease Therapy
Ionis Pharmaceuticals reported positive pivotal trial results for zilganersen, an antisense oligonucleotide targeting Alexander disease, a rare neurological disorder with no approved treatments....
Scholar Rock’s SMA Drug Delayed Amid Manufacturing Site Issues
The FDA has issued a complete response letter for Scholar Rock’s apitegromab SMA treatment following inspection failures and ongoing quality-control issues at a Novo Nordisk-owned contract...
CRISPR Study Differentiates Lung Cancer Growth by EML4-ALK Variants
Researchers used CRISPR genome editing in mice models to reveal that different EML4-ALK gene fusion variants in lung adenocarcinoma drive distinct tumor growth kinetics and responses to treatment....
Sanofi and Eli Lilly Boost Investments and Facilities for Biotech Innovation
Sanofi expanded its venture capital arm with a $625 million cash infusion to invest in biotech startups, reflecting a focus on advancing scientific innovation amid tight capital markets....
Advances in AI-Enabled Drug Discovery: Merck Collaborates with Variational AI
Merck has entered a collaboration with Variational AI, investing up to $349 million to apply cutting-edge generative AI models for designing novel small molecule therapeutics targeting undisclosed...
MBX Biosciences’ Phase 2 Success in Chronic Hypoparathyroidism
MBX Biosciences announced positive top-line phase 2 data for canvuparatide in chronic hypoparathyroidism, meeting its primary endpoint and demonstrating significant improvements in adults. The...
Roche Reveals Broad Phase 3 Breast Cancer Success with SERD Pill
Roche announced a significant phase 3 trial win for its selective estrogen receptor degrader (SERD) in a broad breast cancer population, outperforming standard-of-care treatments. This advancement...
Novel PET Tracer Enables Same-Day Imaging of Aggressive Cancers
Researchers have developed an innovative PET tracer targeting the protein nectin-4, commonly overexpressed in triple-negative breast cancer and urothelial bladder carcinoma. This new tracer...
Pfizer’s $4.9B Metsera Deal: Obesity Pipeline Reloaded
Pfizer has agreed to acquire Metsera for an initial payment of $4.9 billion, with additional milestone payments potentially raising the total to $7.3 billion. This acquisition brings a diverse...
FDA Clears Keytruda’s One-Minute Subcutaneous Injection
The U.S. FDA has approved Merck's Keytruda Qlex, the first subcutaneously administered immune checkpoint inhibitor for solid tumors, enabling dosing in about one minute. This rapid administration...
Ionis’ Zilganersen Meets Pivotal Study Goals for Alexander Disease
Ionis Pharmaceuticals has reported positive top-line results from a pivotal Phase 3 study evaluating zilganersen, an antisense oligonucleotide for Alexander disease, a rare and fatal inherited...
Scholar Rock’s SMA Drug Rejected Over Manufacturing Quality Issues
The FDA has issued a complete response letter rejecting Scholar Rock’s apitegromab, intended for spinal muscular atrophy (SMA), due to unresolved manufacturing problems at a contract facility...
Roche’s Strategy for ‘Top Three’ Obesity Market Position
Roche has unveiled a strategic plan to become a leading obesity company by 2030 without relying on a single blockbuster drug. The plan leverages multiple pipeline assets, including the dual...